Researchers discovered that mice lacking the GPR75 gene gained significantly less weight on a high-fat diet and showed protection against fatty liver disease through two mechanisms: reduced fat absorption in the intestines (particularly in males) and altered brain signaling that affects energy regulation. According to Gram Research analysis, deleting the gene from AgRP brain neurons alone reduced body weight by 10 to 12 percent and decreased fat deposits by 27 to 50 percent, while global gene deletion produced even stronger protection. This finding identifies GPR75 as a potential target for developing new obesity treatments.
Scientists discovered that turning off a gene called GPR75 helps protect against obesity and fatty liver disease in mice, even when eating a high-fat diet. According to Gram Research analysis, the gene works in two ways: it affects how the brain controls hunger and weight, and it influences how the body absorbs fat from food. Male mice without this gene absorbed less dietary fat and excreted more fat in their waste, while both male and female mice showed reduced weight gain. This finding suggests GPR75 could become a target for new obesity treatments in humans.
Key Statistics
A 2026 animal study published in Molecular Metabolism found that mice completely lacking the GPR75 gene gained substantially less weight when fed a high-fat diet compared to normal mice, with male mice showing particularly strong protection against weight gain.
Mice with AgRP neuron-specific GPR75 deletion showed 10 to 12 percent body weight reduction and 27 to 50 percent decrease in white fat deposits in a 2026 study, demonstrating the gene’s role in brain-controlled energy regulation.
Male mice lacking GPR75 excreted significantly more fat in their feces and absorbed less dietary fat from food, indicating the gene controls intestinal fat absorption mechanisms in a 2026 research study.
The Quick Take
- What they studied: How a specific gene called GPR75 controls body weight and fat storage, particularly when eating high-fat foods
- Who participated: Laboratory mice (both male and female) that were genetically modified to lack the GPR75 gene, compared to normal mice
- Key finding: Mice without the GPR75 gene gained significantly less weight on a high-fat diet and showed better protection against fatty liver disease. Male mice also absorbed less dietary fat, excreting more fat in their waste instead of storing it.
- What it means for you: This research identifies a potential new drug target for obesity treatment. However, these are early animal studies, and human treatments are likely years away. People with obesity should continue following current medical advice while researchers develop new therapies based on this discovery.
The Research Details
Researchers created mice that completely lacked the GPR75 gene and compared them to normal mice. They fed both groups either regular chow or a high-fat diet and measured how much weight they gained, how much food they ate, how much energy they burned, and how much fat they absorbed from food. To understand which parts of the body were responsible for the protective effects, the scientists also created mice missing the GPR75 gene only in specific tissues: the liver, intestines, blood vessels, and a specific brain region called AgRP neurons. This allowed them to pinpoint exactly where the gene matters most.
The researchers measured multiple aspects of metabolism, including food intake, energy expenditure, fat burning, intestinal fat absorption, and liver fat accumulation. They also examined how much fat was excreted in the mice’s feces, which indicates how much dietary fat was not absorbed by the body.
This approach is important because it moves beyond simply observing that a gene is associated with obesity protection. By systematically removing the gene from different tissues, the researchers could identify the specific mechanisms and body systems involved. This type of detailed investigation helps scientists understand how to design drugs that target the right tissues and avoid unwanted side effects.
This is a well-designed animal study published in a peer-reviewed scientific journal. The researchers used multiple complementary approaches to understand the gene’s function, tested both male and female mice, and examined multiple metabolic pathways. However, animal studies do not always translate directly to humans, so these findings need confirmation in human research before clinical applications.
What the Results Show
Mice lacking the GPR75 gene showed marked resistance to weight gain when fed a high-fat diet. The protection was particularly strong in male mice, which gained substantially less weight than normal mice eating the same diet. Interestingly, this weight protection did not occur because the knockout mice ate less food. Instead, the researchers found two distinct mechanisms at work.
In male mice, the primary mechanism involved reduced fat absorption from food. These mice absorbed significantly less dietary fat and excreted much more fat in their feces, meaning the fat passed through their digestive system without being stored in the body. Additionally, the knockout mice showed changes in how they used energy, burning less fat and relying more on carbohydrates for fuel.
When the researchers deleted the GPR75 gene only from AgRP neurons (a specific brain region involved in appetite and energy regulation), they observed weight loss of 10 to 12 percent in both male and female mice, with white fat deposits shrinking by 27 to 50 percent. However, this effect was smaller than what occurred when the gene was deleted from the entire body, indicating that other tissues also contribute to the protective effect.
Mice lacking GPR75 showed protection against hepatic steatosis, which is fatty liver disease. The global knockout mice also demonstrated improved metabolic health markers. When the gene was deleted only from the liver, intestines, or blood vessel cells, the protective effects against obesity were not observed, suggesting these tissues alone are not responsible for the main protective mechanism. This finding was important because it ruled out certain tissues as primary targets and pointed toward the brain and other mechanisms as more important.
Previous research in humans showed that people with genetic variants that reduce GPR75 function tend to weigh less and have lower obesity risk. This animal study provides the first detailed explanation of how this protection works. The findings align with the human genetic associations and provide mechanistic insight into why GPR75 variants protect against obesity. The discovery that both brain and intestinal mechanisms contribute to the effect is novel and expands understanding beyond what human genetic studies alone could reveal.
This research was conducted in mice, which do not always behave identically to humans. The protective effect against weight gain was stronger in male mice than female mice, suggesting sex differences that may or may not apply to humans. The study did not identify which specific peripheral tissue (outside the brain) is responsible for the reduced fat absorption in males, only that it is not the liver, intestines, or blood vessel cells tested. Additionally, the study examined only one high-fat diet composition, so results might differ with other dietary patterns. Finally, these findings represent early-stage research, and many years of additional study would be needed before any human treatments could be developed.
The Bottom Line
This research is preliminary and does not yet support any changes to current obesity treatment approaches. People seeking to manage weight should continue following established medical advice: maintain a balanced diet, engage in regular physical activity, and consult healthcare providers about evidence-based treatments. This study provides strong evidence that GPR75 warrants further investigation as a potential drug target, but human clinical trials would be necessary before any new treatments become available.
This research is most relevant to people with obesity or at high risk for obesity, individuals with fatty liver disease, and researchers developing new obesity medications. It may also interest people with a family history of obesity. However, the findings do not yet apply to clinical practice. People should not expect GPR75-targeted treatments to be available in the near term.
This is fundamental research identifying a potential therapeutic target. Typically, 5 to 10 years or more of additional research would be needed to develop and test a drug targeting GPR75 in humans. Clinical trials would follow, potentially adding several more years before any treatment becomes available to patients.
Frequently Asked Questions
How does the GPR75 gene affect weight gain and obesity?
GPR75 controls weight through two pathways: brain signals that regulate hunger and energy use, and intestinal absorption of dietary fat. When the gene is absent, the body absorbs less fat from food and burns energy differently, resulting in reduced weight gain even on high-fat diets.
Could GPR75 blocking become a treatment for obesity in humans?
GPR75 shows promise as a drug target based on animal research and human genetic studies. However, developing and testing a safe, effective human treatment would require 5 to 10 years or more of additional research, including clinical trials.
Why did male and female mice respond differently to GPR75 deletion?
Male mice showed stronger protection against weight gain, particularly through reduced intestinal fat absorption. Female mice showed some protection through brain mechanisms but not the intestinal fat-absorption effect, suggesting sex-specific differences in how the gene functions.
Does this research mean I should change my diet or weight management approach now?
No. This is early-stage animal research. Current evidence-based approaches (balanced diet, regular exercise, medical consultation) remain the best strategies. GPR75-targeted treatments are not yet available and may take years to develop.
What is hepatic steatosis and why does GPR75 deficiency help prevent it?
Hepatic steatosis is fatty liver disease, where excess fat accumulates in liver cells. GPR75 deficiency reduces overall fat absorption and storage, which decreases the amount of fat available to accumulate in the liver, providing protection against this condition.
Want to Apply This Research?
- Users interested in obesity research could track their dietary fat intake (grams per day) and body weight weekly to monitor personal trends while awaiting future GPR75-targeted treatments. This establishes a baseline for comparison if new therapies become available.
- While GPR75 treatments are not yet available, users can optimize fat absorption and utilization through dietary choices: increase soluble fiber intake (which can reduce fat absorption), maintain consistent meal timing, and balance macronutrients. The app could remind users to log these dietary factors and track how they correlate with weight and energy levels.
- Set up a long-term tracking dashboard monitoring weekly weight, dietary fat intake, physical activity, and energy levels. As research progresses and GPR75-targeted treatments potentially become available, this historical data would help users and their doctors assess treatment effectiveness compared to their baseline.
This article summarizes early-stage animal research and does not constitute medical advice. GPR75-targeted treatments are not currently available for human use. People with obesity or metabolic concerns should consult qualified healthcare providers about evidence-based treatment options. This research represents preliminary findings that require extensive additional study, including human clinical trials, before any therapeutic applications could be developed. Do not delay or avoid seeking current medical care based on this research.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.